JFG
SABS icon

Jefferies Financial Group’s SAB Biotherapeutics SABS Stock Holding History

Jefferies Financial Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.46M Buy
903,094
+322,766
+56% +$1.29M 0.02% 431
2025
Q4 		$2.17M Buy
+580,328
New +$1.91M 0.01% 776

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jefferies Financial Group's SABS Position: Q1 2026 in Review

Jefferies Financial Group increased its SAB Biotherapeutics (SABS) stake by 56% in Q1 2026, buying an estimated $1.29M and bringing the position to 903,094 shares worth $3.46M. The position accounts for 0.02% of the portfolio, ranked #431.

Jefferies Financial Group first reported a position in SABS in Q4 2025 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Jefferies Financial Group held 903,094 shares of SAB Biotherapeutics worth $3.46M as of Q1 2026.
  • Jefferies Financial Group bought 322,766 SAB Biotherapeutics shares in Q1 2026, an estimated $1.29M.
  • SAB Biotherapeutics made up 0.02% of Jefferies Financial Group's portfolio in Q1 2026, its #431 holding.
  • Jefferies Financial Group first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.